Verification evidence is still being completed.
PDF / print export
Memo Therapeutics AG
Schlieren, Switzerland
- Verified lead
- Erik van den Berg
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Antibody Discovery, DROPZYLLA Microfluidic Platform, and BK Polyomavirus Therapeutics
- Review cycle
- 24 April 2026
- Full address
- Wagistrasse 27, 8952 Schlieren, Switzerland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Memo Therapeutics press release on the Series C financing quoting CEO Erik van den Berg.
- Editorial note
- Schlieren late-stage antibody biotech with named CEO, DROPZYLLA discovery platform, 45 million CHF Series C, and a February 2026 CSL collaboration worth up to 328 million USD.
Antibody Discovery, DROPZYLLA Microfluidic Platform, and BK Polyomavirus Therapeutics
45 million CHF Series C, CSL collaboration and option agreement, Phase II potravitug program
Schlieren late-stage antibody biotech with named CEO, DROPZYLLA discovery platform, 45 million CHF Series C, and a February 2026 CSL collaboration worth up to 328 million USD.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Schlieren, Switzerland
Memo Therapeutics AG
Antibody Discovery, DROPZYLLA Microfluidic Platform, and BK Polyomavirus Therapeutics · Late-stage clinical antibody development
Schlieren late-stage antibody biotech with named CEO, DROPZYLLA discovery platform, 45 million CHF Series C, and a February 2026 CSL collaboration worth up to 328 million USD.
- Lead
- Erik van den Berg (verified ↗)
- Address
- Wagistrasse 27, 8952 Schlieren, Switzerland (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Late-stage clinical antibody development
- Capabilities
- DROPZYLLA Antibody Repertoire Copying · Microfluidic Single-Cell Processing · Clinical Antibody Development for BKPyV
- Founded
- 2012
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Erik van den Berg
Chief Executive Officer
Full addressWagistrasse 27, 8952 Schlieren, Switzerland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
Swiss Biotech Association listing for Memo Therapeutics AG in Schlieren.
Open sourceLate-stage clinical antibody development
Schlieren, Switzerland. Antibody Discovery, DROPZYLLA Microfluidic Platform, and BK Polyomavirus Therapeutics. Review completed on 24 Apr 2026.
Swissmedic, EMA, and FDA for clinical-stage oversight
45 million CHF Series C, CSL collaboration and option agreement, Phase II potravitug program
Antibody Discovery, DROPZYLLA Microfluidic Platform, and BK Polyomavirus Therapeutics
Schlieren late-stage antibody biotech with named CEO, DROPZYLLA discovery platform, 45 million CHF Series C, and a February 2026 CSL collaboration worth up to 328 million USD.
Editorial note
Memo Therapeutics anchors Swiss antibody-discovery biotech with a named CEO, a 45 million CHF Series C, a Phase II potravitug program for BKPyV, and a February 2026 CSL collaboration and option agreement.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
DROPZYLLA Antibody Repertoire Copying
Microfluidic Single-Cell Processing
Clinical Antibody Development for BKPyV
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
DROPZYLLA microfluidic platform
Single-cell B-cell processing
Clinical trial operations
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Memo Therapeutics AG located?
- Memo Therapeutics AG operates from Wagistrasse 27, 8952 Schlieren, Switzerland, Schlieren, Switzerland.
- Who runs Memo Therapeutics AG?
- Memo Therapeutics AG is led by Erik van den Berg, Chief Executive Officer. Verified 24 Apr 2026.
- What does Memo Therapeutics AG do?
- Schlieren late-stage antibody biotech with named CEO, DROPZYLLA discovery platform, 45 million CHF Series C, and a February 2026 CSL collaboration worth up to 328 million USD. Core capabilities: DROPZYLLA Antibody Repertoire Copying, Microfluidic Single-Cell Processing, Clinical Antibody Development for BKPyV.
Editorial context
Related technical briefs
Briefs that name Schlieren as a covered market or city.